Fibrocell Reports Phase II azficel-T Trial for Treatment of Vocal Cord Scarring Did Not Meet Primary Endpoints
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Wall St rises as oil slide offers respite after Fed rate hike
- Oil falls 2% to one-week low as Middle East supply disruption fears ease
- The Fed is hiking. Why isn't UBS worried about stocks?
- Wall Street on Fed rate hike: 'As hawkish as it gets'
- RBC bullish on Kraft Heinz, sees return to growth in 2027
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Shipping stocks on fire — but cracks are forming in the rate rally
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
- GlobalFoundries and Marvell expand SiGe capacity for optical networking
Wedbush Remains Sidelined on Fibrocell Science (FCSC) Following Azficel-T Program Failure
June 9, 2016 8:47 AM EDTWedbush maintained a Neutral rating on Fibrocell Science (NASDAQ: FCSC), and cut the price target to $1.50 (from $4.00), as the company reports failure of the azficel-T program. FCSC reported that azficel-T missed the primary endpoints assessing change from baseline at four months in mucosal wave... More
Roth Affirms Fibrocell Science (FCSC) at 'Buy' Following Azficel-T Phase 2 Miss in Vocal Cord Scarring
June 8, 2016 11:59 AM EDTRoth Capital affirms Fibrocell Science, Inc. (Nasdaq: FCSC) at Buy with a price target of $5 after the company announced that primary endpoints were not... More
